Filing Flows › Teva Pharmaceutical Industries (TEVA) › Q1 2025
Teva Pharmaceutical Industries (TEVA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Teva Pharmaceutical Industries (TEVA) reported revenue of $3.9B for the first quarter 2025 (Q1 2025), +2% from a year earlier and -8% from the quarter before. Operating margin was 13.3%, net earnings $214M (5.5% of revenue).
Teva Pharmaceutical Industries, Q1 2025: revenue $3.9B (+2% year over year), operating margin 13.3%, net earnings $214M, operating cash flow −$105M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.9B | -8% | +2% |
| Gross profit | $1.9B | -12% | +6% |
| Operating profit | $519M | — | — |
| Net earnings | $214M | — | — |
| Operating cash flow | −$105M | — | — |
What changed
Revenue was $3.9B in Q1 2025, up 2% year over year and down 8% from the previous quarter. Sale of Goods was the largest line at 87% of revenue. Sale of Goods added $0.13B year over year (up 4%), 178% of the total change. Other declined 37%.
Gross margin was 48.2%, up 1.9 points from a year earlier. Operating profit was $0.52B, a 13.3% margin (up 19.0 points year over year). Operating expenses fell 32% while revenue rose 2%. Net earnings were $0.21B. The effective tax rate was 25.2%.
Operating cash flow was −$0.10B. Non-cash charges added back $0.24B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items used $0.60B. Capital expenditures of $0.13B exceeded it, leaving free cash flow of −$0.23B.
Questions
What was Teva Pharmaceutical Industries' revenue in the first quarter 2025?
Teva Pharmaceutical Industries (TEVA) reported revenue of $3.9B for the first quarter 2025 (Q1 2025), +2% from a year earlier and -8% from the quarter before.
Was Teva Pharmaceutical Industries profitable in the first quarter 2025?
Operating profit was $519M (13.3% of revenue) and net earnings $214M.